Becton Dickinson & Co. Q4 FY2026 Earnings Call Summary
BDX
NYSE
Healthcare
📅 2026-11-05
⏱ ~60 sec read
🟢 Bullish
⏱️ 60-Second Brief
Becton Dickinson & Co. · Q4 FY2026
Stock Next Day
▼ 0.78%
$213.55 → $211.88
Revenue
$5.3B
EPS
$48.3
AI Sentiment
🟢 Bullish
The company delivered strong financial results, successfully…
📌 Bottom Line:
BD reported a strong fiscal fourth quarter, with revenue reaching $5.3 billion and adjusted diluted earnings per share climbing to $4.15, significantly exceeding prior year figures. This performance caps a transformative…
🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy.
·
⚠️ Not financial advice. For informational purposes only.
Full Disclaimer →
📋 TL;DR — What Happened
BD reported a strong fiscal fourth quarter, with revenue reaching $5.3 billion and adjusted diluted earnings per share climbing to $4.15, significantly exceeding prior year figures. This performance caps a transformative year for the company, which successfully spun off its Life Sciences business to become a more focused medical technology leader, positioning it for durable long-term growth.
📊 Key Financial Metrics
Revenue
$5.3B
EPS (Diluted)
$48.3
AI Sentiment
🟢 Bullish
The company delivered strong financial results, successfully completed a major strategic transformation, and provided optimistic guidance for the upcoming fiscal year, indicating robust underlying business health and future growth potential.
✅ What Went Well
BD delivered a robust fourth quarter, with revenue growth of 5.6% on a foreign currency-neutral basis and adjusted diluted EPS growth of 27.3%, demonstrating excellent execution and demand across its core medical technology platforms. This strong finish contributed to full-year revenue growth of 3.9% FXN and adjusted diluted EPS of $12.70.
The completion of the spin-off of the Life Sciences business in fiscal 2026 was a pivotal strategic achievement, allowing BD to sharpen its focus as a dedicated MedTech company. This transformation is expected to enhance core growth, accelerate innovation, and drive greater productivity, as highlighted by CEO Tom Polen.
The company showcased impressive financial health with a 30.0% increase in cash from continuing operations to $3.6 billion and a 42.5% rise in free cash flow to $2.9 billion for the full fiscal year. This robust cash generation provides ample resources for strategic investments, debt reduction, and potential shareholder returns.
The landmark partnership with the U.S. Government, involving a planned $19 billion investment in the U.S. (including $3 billion for manufacturing expansion), is a significant win. This not only strengthens critical medical supply chains but also provides relief from future tariffs, securing a more stable operating environment for BD.
BD continues to drive innovation, evidenced by the U.S. launch of the BD® Liverty™ TIPS Stent Graft, positive nine-month results from the AGILITY clinical trial for the BD® Revello™ Vascular Covered Stent, and significant enrollment milestones in the STANCE and PREVENT clinical trials for advanced tissue regeneration products. These advancements underscore the company's commitment to addressing unmet patient needs and expanding its market leadership.
⚠️ Concerns & Risks
The company acknowledges ongoing risks from macroeconomic conditions, including persistent inflationary pressures, currency and interest rate fluctuations, and increased borrowing costs, which could impact operational expenses and consumer spending on healthcare.
Geopolitical developments, particularly in regions like the Middle East, Ukraine, and Asia, pose risks to global transportation networks, energy supplies, and the overall supply chain, potentially leading to higher costs for raw materials and components, and delays in product delivery.
BD operates in a highly competitive market, facing challenges from changing customer and patient preferences, the introduction of new products and novel medical therapies by competitors, and the rapid evolution of technologies, including emerging applications of artificial intelligence (AI), which necessitate continuous innovation and adaptation.
The company is subject to stringent regulatory requirements, and any issues related to product efficacy, safety concerns, non-compliance, or changes to labeled indications could result in product recalls, lost revenue, restrictions on sales, or civil penalties, impacting financial performance and reputation.
Changes in reimbursement practices, coverage policies, and third-party payer cost containment measures, along with potential cuts or freezes in healthcare spending by governments (such as China’s volume-based procurement tender process), could lead to reduced demand for BD's products or downward pricing pressure.
🔮 CEO / Management Guidance
For fiscal year 2027, BD's management provided guidance anticipating low single-digit revenue growth on both a GAAP and foreign currency-neutral basis. The company projects adjusted diluted earnings per share to be in the range of $13.10 to $13.30, reflecting confidence in the "New BD's" ability to deliver durable performance and strong cash flow potential.
💬 Key Quote
Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company... We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD." — Tom Polen, chairman, CEO and president
📅 Quarter-over-Quarter Comparison
Comparing Q4 FY2026
vs Q3 FY2026
All quarters →
Revenue
$5.0B
→
$5.3B
EPS
$12.62
→
$48.3
Sentiment
🟢 Bullish
→
🟢 Bullish
Stock Reaction
-0.28%
→
-0.78%
🏢 About Becton Dickinson & Co.
Becton Dickinson & Co. (BDX) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.
📈 Want to act on this insight?
Topics:
Medical Technology
Strategic Transformation
Earnings Growth
Supply Chain Resilience
Product Innovation
📁 More from Becton Dickinson & Co.
View all earnings summaries for Becton Dickinson & Co. →